| Research purposes: To observe the slow release performance of compound artificialmaterials carrying triple chemotherapy medicine HRZ calcium sulfate/poly amino acid withinthe model body of rabbit spinal tuberculosis.Experimental research methods:36New Zealand white rabbits, each of which withbody weight as3±0.5kg and all of which is divided into three groups of A, B, and C in arandom way. Group A is the experiment one with tuberculosis models and the compoundartificial materials carrying triple chemotherapy medicine HRZ calcium sulfate/poly aminoacid are implanted into the site of defect resulting from debridement of the lesion of the L4-5rabbit spinal tuberculosis model. Group B is the control group of the tuberculosis modelwhere the compound artificial materials do not carry medicine calcium sulfate/poly aminoacid are implanted into the site of defect resulting from debridement of the lesion of the L4-5rabbit spinal tuberculosis model. Group C is the blank control group where a regular bonegroove, the size of which is5mm (length)*3.5mm (width)*3.5mm (depth), is cut at thelaterior anterior part to the left side of the Centrum L4-5of healthy big rabbits, and artificialmaterials not carrying medicine calcium sulfate/poly amino acid is implanted into this bonegroove. Three experimental animals are killed in a random way at the end of Week2, Week4,Week8, and Week12respectively, and the inferior vena venous blood, vertebral body bonegraft, and the psoas major of the surface of the ill vertebral of every experimental animal aretaken off as the experimental specimen, which is treated and then tested with highperformance liquid chromatography (HPLC) to get the drug concentrations of theaforementioned different tissue specimens.Results: In Group A, concentrations of isoniazid, rifampicin, and pyrazinamide at theWeek2and Week4after the operation have reached the level able to kill bacteria in the vertebral body and psoas major of the ill centrum and the level to inhibit bacteria in venousblood. At the end of Week8and Week12after operation these three drugs have all reachedthe levels of concentration able to inhibit bacteria in the vertebral body and psoas major of theill centrum, but they are very low or even could not be detected in venous blood. Within theaforementioned time periods, no drug concentration has been detected within the vertebralbody and psoas major of the ill centrums in Group B and Group C, and the tested results areapplied to baseline proofreading.Experimental Conclusion: The MBC of INH in the bone tissue and psoas major of theill centrums could last to the eighth week after operation and is still in MIC at the end ofWeek12. The drug concentration in venous blood at the end of Week2after operation isMBC, and the MIC could last to the eighth week after the operation. Nothing is detected at theend of Week12. MBC of RFP in the bone tissue and psoas major of the ill centrums could lastto the fourth week after operation, and the drug concentration at the end of the eighth weekafter operation is MIC. No drug concentration is detected at the end of Week12. The MICwithin the venous blood could last to the second week after the operation, and the drugconcentration at the fourth week after the operation has not reached MBC in addition that nodrug concentration has been detected at the end of the eighth and twelfth week. The MICwithin the bone tissue and psoas major of the ill centrums could last to the eighth week afterthe operation, and the drug concentration at the twelfth week after the operation is MIC; whilethe drug concentration in the venous blood at the end of the eighth week is MIC, and no drugconcentration has been detected at the end of the twelfth week. |
PDF Full Text Request